Protagonist Therapeutics PTGX 深 沪
已收盘 09-19 16:00:00 美东时间
62.20
+0.060
+0.10%
华盛通- 最 高63.30
- 今 开62.22
- 成交量 246.17万股
- 最 低 61.635
- 昨 收 62.14
- 总市值 38.55亿
- 52周最高 63.30
- 市盈率 静 14.71
- 换手率 3.97%
- 52周最低 33.31
- 委 比 -72.97%
- 总股本 6198.20万
- 历史最高 63.30
- 量 比 2.72
- 振 幅 2.68%
- 历史最低 4.47
- 每 手 1
- 风险率 6.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews
During the last three months, 4 analysts shared their evaluations of Protagonis...
09-18 04:01
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
Protagonist And J&J Submit EMA Application For Icotrokinra After Four Phase 3 Trials Show Superiority In Plaque Psoriasis With Once-Daily Oral Tablet
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented
09-11 20:11
Protagonist Plans Year-End FDA Filing for Rusfertide After Strong Phase 3 Results in Blood Disorder Therapy
Protagonist Therapeutics, Inc. ("Protagonist" or "the Company") announced today that rusfertide, a potential first-in-class hepcidin-mimetic peptide, has been granted Breakthrough Therapy Designation by the U.S. Food and
08-25 19:09
What 4 Analyst Ratings Have To Say About Protagonist Therapeutics
In the preceding three months, 4 analysts have released ratings for Protagonist...
08-08 02:01
JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $69
JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $67 to $69.
08-07 21:37
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Protagenic Therapeutics received a patent (JP 7714571B) in Japan for a modified stilbenoid to treat epilepsy and seizures. The patent, granted on July 18, 2025, provides exclusivity until March 2041. Colin Stott highlighted the importance of this patent, following its previous grant in the UK, and plans to expand its coverage in other territories. Japan's pharmaceutical market is the world's third largest, valued at over $85 billion in 2025 and e...
07-30 12:30
口服多肽向FDA递交上市申请 药明康德共同强生等参与
据药明康德（603259.SH）官微7月22日消息，药明康德共同强生（Johnson & Johnson）与Protagonist Therapeut...
07-22 09:22
Protagonist Therapeutics And Johnson & Johnson Submit NDA For Icotrokinra, A First-in-Class Oral IL-23 Receptor Blocker, Following Phase 3 Results In Plaque Psoriasis
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptorFiling based on unprecedented data package that met all primary endpoints across four Phase 3 studies,
07-21 20:06
